You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Pathophysiology/Complications
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Authors

  • Munehiro Kitada Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Shin-ichi Tsuda Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Kazunori Konishi Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Ai Takeda-Watanabe Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Mizue Fujii Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Keizo Kanasaki Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Makoto Nishizawa Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Atsushi Nakagawa Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan PubMed articlesGoogle scholar articles
  • Daisuke Koya Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Munehiro Kitada; kitta{at}kanazawa-med.ac.jp
View Full Text

Citation

Kitada M, Tsuda S, Konishi K, et al
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
BMJ Open Diabetes Research and Care 2017;5:e000391. doi: 10.1136/bmjdrc-2017-000391

Publication history

  • Received January 14, 2017
  • Revised April 21, 2017
  • Accepted May 15, 2017
  • First published July 7, 2017.
Online issue publication 
July 06, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/